Crucell Terug naar discussie overzicht

Crucell & ADImmune Corporation.

1. [verwijderd] 22 september 2008 09:51

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   wilb52 schreef:

   The nurses ( 5 in a row ) have just concluded the same, because I am not allowed to hold the paper myself , for I am too dangerous to the PPS of Crucell, so they told me.
   With all those 25 different names to post , it is difficult , not making mistakes, and that's why they protect me against myself.
   What a lovely nursery.
   
   Happy to be here again, after a weekend abroad
   
   (:->D)
   

   Zal ik een keer op bezoek komen of is het een gesloten? :-))
   Ik kan wat wijn meesmokkelen...
2. flosz 22 september 2008 09:51

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   quote:

   wilb52 schreef:

   The nurses ( 5 in a row ) have just concluded the same, because I am not allowed to hold the paper myself , for I am too dangerous to the PPS of Crucell, so they told me.
   With all those 25 different names to post , it is difficult , not making mistakes, and that's why they protect me against myself.
   What a lovely nursery.
   
   Happy to be here again, after a weekend abroad
   
   (:->D)
   

   Drie van de vijf........
   
   sammie, vertel grappenflapper danza ook nog even over de naamswijziging in Meerkanten(sinds 1 jan. 2000 DUH).

   Bijlage:
3. [verwijderd] 28 september 2008 10:58

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Weer iets uitgebreider:
   
   ADImmune Corp. Eyes Bigger Share of Global Vaccine Business
   
   2008/09/26
   Taipei, Sept. 26, 2008 (CENS)--Steve Chan, chairman of local biotechnology firm ADImmune Corp., recently said that his company looks to grabbing a certain share in the global vaccine market over the next few years.
   
   Only three months after Chan took over as chairman at ADImmune, the company raised another NT$2.5 billion (US$78.37 million at US$1: NT$31.9) through capital increase and syndicated bank loans.
   
   According to Chan, ADImmune has received technical transfer from and engaged in cooperative projects with Crucell, a major vaccine maker based in the Netherlands, as well as licensing in Taiwan, Japan, Macau etc. in 2007. He stressed that his company would continue to seek international partnerships to develop newer, better vaccines.
   
   ADImmune raised NT$1.2 billion (US$37.62 million) via a capital increase in the first half and completed the project by selling each share for NT$20.5 (US$0.64), with investors including state-run companies as China Steel Corp., Taiwan Fertilizer Corp., as well as Industrial Bank of Taiwan, Fubon Bank, Yulon Group, and two institutional investors JAIC and BHP.
   
   Chan claimed that Taiwan boasts world-class R&D skills in enterovirus-vaccine. With continually expanding global vaccine market, the trend creates very good opportunities for the biotechnology industry in Taiwan.
   
   Chan said that his company would continue try to engage in cooperation projects with the final winner of a government-backed build-own-operate (BOO) tender for locally manufactured flu-vaccines, with the tender facing uncertainties for the original winner of the tender having been acquired by another company.
   
   (by Quincy Liang)
   cens.com/cens/html/en/news/news_inner...
4. flosz 30 april 2009 00:37

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Uit de swinefludraad met dank aan the banger.
   
   www.etaiwannews.com/etn/news_content....
   
   Local pharmaceutical companies prepare to develop swine flu vaccine
   TAIPEI, Taiwan -- Taiwan has been in contact with the United States, seeking samples of the H1N1 swine flu virus strain so that local pharmaceutical companies can start developing a human vaccine against the virus that emerged in Mexico last week, Health Minister Yeh Chin-chuan said Wednesday.
   
   Yeh said at the Legislative Yuan that the Department of Health (DOH) has also instructed the non-profit National Health Research Institute (NHRI) to prepare for developing the vaccine.
   He said the NHRI is capable of producing vaccine in emergency situations and that an expanded vaccine plant run by Adimmune Corp., also known as Kuo Kwang Biotechnology, is expected to be inaugurated by June.
   The Adimmune vaccine plant, which will be the largest of its kind in Asia with a maximum annual capacity of 30 million doses of vaccine, will allow production of human vaccine against swine flu to be significantly ramped up, Yeh noted.
   Noting that the World Health Organization (WHO) is working on a global H1NI vaccine production plan, Yeh said the country will take part in the global action in line with WHO instructions.
   www.chinapost.com.tw/taiwan/national/...
   
   Local firm Adimmune Corp said separately yesterday that if asked by the government, it would cancel all orders and produce only H1N1 swine flu vaccine.
   
   A spokesman said that Adimmune could produce up to 24 million doses of vaccine within three to six months of receiving a sample of the H1N1 strain of swine flu.
   
   Adimmune, Taiwan’s only private manufacturer of vaccines for humans, produces vaccines for the flu, Japanese encephalitis, tetanus and tuberculosis.
   www.taipeitimes.com/News/taiwan/archi...
   
   www.iex.nl/forum/topic.asp?forum=228&...
5. flosz 30 april 2009 00:53

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Ook nog even erbij:
   Leiden, The Netherlands, March 22, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has completed an influenza alliance with Taiwanese-based ADImmune Corporation. Under the terms of the deal, ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune.
   www.iex.nl/forum/topic.asp?forum=228&...
   *****************
   
   Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO. www.crucell.com/feature_Swineflu_stat...
   
   
6. flosz 5 mei 2009 19:42

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   www.youtube.com/watch?v=6Ym98nHPtVM
7. flosz 6 juni 2009 15:56

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Holdings: 12% AdImmune Corporation (private)
   Slide 5.
   
   ipv 20%.
   
8. flosz 11 juni 2009 20:12

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Adimmune Corp., the only private human vaccine manufacturer in Taiwan, announced that starting in late May it began receiving in succession vaccine strains of the influenza A (H1N1) virus from Australia, from the National Institute for Biological Standards and Control in the United Kingdom, and from Centers for Disease Control and Prevention in the United States. These strains are now undergoing “biological safety-level No. 2, passage evaluation” tests in virus-seed labs, in which the strains are cultivated at an amplified level. The next step will be for Adimmune to select the vaccine strains most suitable for production. Preliminary preparations for the mass production of a vaccine should be completed by the middle of July, the company said.(CY-HZW)
   taiwanjournal.nat.gov.tw/ct.asp?xItem...
   
9. flosz 13 juni 2009 19:36

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Taiwan to increase purchase of vaccine after pandemic declaration
   
   Taiwan News, Staff Writer
   2009-06-12 06:07 PM
   
   TAIPEI (Taiwan News) – As the World Health Organization raised H1N1 flu alert to pandemic level, the Central Epidemic Command Center (CECC) announced today to increase overseas purchase of flu vaccines to 5 million shots.
   Health Minister Yeh Ching-chuan said Friday the government would double the number of overseas vaccine procurement to 5 million from 2.5 million shots, which, along with 5 million seasonal flu vaccines, will be available for injection in early autumn.
   Adimmune Corp., a Taichung-based manufacturer of flu vaccines, said the production capacity of its new plant was up to 30 million vaccines. After necessary procedures of factory certification, human test, and vaccine registration are completed, domestically manufactured H1N1 flu vaccines can hit the market in October at the earliest, said the company.
   According to a foreign pharmaceutical company, the mass production of new flu vaccine has just begun, and will be ready for delivery in August or September.
   The CECC proclaimed new measures on Friday following a meeting between Cabinet officials and experts: speed-up of purchases and stockpiling of necessary materials in the wake of a second wave of flu spread; full monitoring of virus activities in the place of report system by doctors; strengthening health insurance resources in treatment of patients.
   The Center also advised major international events including World Games in Kaohsiung and Deaflympic Games in Taipei to be held as scheduled, claimed the Executive Yuan will draft a special statute to be reviewed by the Legislative Yuan, and urged the public to cooperate with government’s disease-prevention measures.
   The Department of Health (DOH) announced to shift the focus of the combat against the disease from “blocking its spread” to “decreasing its severity” by speeding up stockpiles.
   DOH Center for Disease Control Director-General Kuo Hsu-sung said Taiwan so far had good efforts in prevention of flu spread, but should make full preparations for outbreaks within community.
   
   tinyurl.com/mtlkmx
   
   Zie ook post go:
   www.iex.nl/forum/topic.asp?forum=228&...
10. harvester 13 juni 2009 20:05

    auteur info

    • harvester

      Lid sinds: 01 apr 2004

      Laatste bezoek: 06 apr 2025

    • Aanbevelingen

      Ontvangen: 2008

      Gegeven: 1894

    •    Aantal posts: 4.199

    mooi, is dus virosome vaccine van crucell (inflexal) met gelijk een aardige afzet 5 mln in Taiwan zelf via 20% deelneming in Adimmune.
    Hopelijk bestelt Japan niet te veel anders blijft er niets over om aan Crucell te leveren voor andere markten.
    
    

    quote:

    flosz schreef:

    Taiwan to increase purchase of vaccine after pandemic declaration
    
    Taiwan News, Staff Writer
    2009-06-12 06:07 PM
    
    TAIPEI (Taiwan News) – As the World Health Organization raised H1N1 flu alert to pandemic level, the Central Epidemic Command Center (CECC) announced today to increase overseas purchase of flu vaccines to 5 million shots.
    Health Minister Yeh Ching-chuan said Friday the government would double the number of overseas vaccine procurement to 5 million from 2.5 million shots, which, along with 5 million seasonal flu vaccines, will be available for injection in early autumn.
    Adimmune Corp., a Taichung-based manufacturer of flu vaccines, said the production capacity of its new plant was up to 30 million vaccines. After necessary procedures of factory certification, human test, and vaccine registration are completed, domestically manufactured H1N1 flu vaccines can hit the market in October at the earliest, said the company.
    According to a foreign pharmaceutical company, the mass production of new flu vaccine has just begun, and will be ready for delivery in August or September.
    The CECC proclaimed new measures on Friday following a meeting between Cabinet officials and experts: speed-up of purchases and stockpiling of necessary materials in the wake of a second wave of flu spread; full monitoring of virus activities in the place of report system by doctors; strengthening health insurance resources in treatment of patients.
    The Center also advised major international events including World Games in Kaohsiung and Deaflympic Games in Taipei to be held as scheduled, claimed the Executive Yuan will draft a special statute to be reviewed by the Legislative Yuan, and urged the public to cooperate with government’s disease-prevention measures.
    The Department of Health (DOH) announced to shift the focus of the combat against the disease from “blocking its spread” to “decreasing its severity” by speeding up stockpiles.
    DOH Center for Disease Control Director-General Kuo Hsu-sung said Taiwan so far had good efforts in prevention of flu spread, but should make full preparations for outbreaks within community.
    
    tinyurl.com/mtlkmx
    
    Zie ook post go:
    www.iex.nl/forum/topic.asp?forum=228&...
    

12. flosz 13 juni 2009 20:09

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    quote:

    harvester schreef:

    20% deelneming in Adimmune.
    

    Deelneming is 12%.
13. [verwijderd] 14 juni 2009 17:32

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    harvester schreef:

    mooi, is dus virosome vaccine van crucell (inflexal) met gelijk een aardige afzet 5 mln in Taiwan zelf via 20% deelneming in Adimmune.
    Hopelijk bestelt Japan niet te veel anders blijft er niets over om aan Crucell te leveren voor andere markten.
    

    Met Japan bedoel je Taiwan?
    En die overseas H1N1 afzet van 5 mln (opgevoerd van eerdere bestelling van 2.5 mln) van een buitenlandse producent is 'dus' waarschijnlijk niet van Crucell. Is m.i. waarschijnlijk van Sanofi, Novartis of GSK.
    
    Daarnaast brengt Adimmune dus zijn eigen vaccins H1N1 (flu antigen, zonder virosomen) op de markt (in ieder geval de Taiwainese) in October.
    Of Adimmune, naast het contract met Crucell voor gewone griep, ook H1N1 antigen aan Crucell gaat leveren, om in virosomen te verwerken in een speciale 'H1N1 Inflexal', is nog volledig onduidelijk. Ik zou zeggen: dat is een nieuwe overeenkomst, en zou in een PB gemeld moeten worden. Maar ja, bij Crucell weet je het nooit: soms melden ze elk mini-licentietje, en tegenwoordig LIJKEN ze heeeel weinig te melden....
    
    
14. harvester 14 juni 2009 18:16

    auteur info

    • harvester

      Lid sinds: 01 apr 2004

      Laatste bezoek: 06 apr 2025

    • Aanbevelingen

      Ontvangen: 2008

      Gegeven: 1894

    •    Aantal posts: 4.199

    uit bovenste post van flosz:
    
    ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune. Financial details were not disclosed.
    
    

    quote:

    maxen schreef:

    [quote=harvester]
    mooi, is dus virosome vaccine van crucell (inflexal) met gelijk een aardige afzet 5 mln in Taiwan zelf via 20% deelneming in Adimmune.
    Hopelijk bestelt Japan niet te veel anders blijft er niets over om aan Crucell te leveren voor andere markten.
    [/quote]
    Met Japan bedoel je Taiwan?
    En die overseas H1N1 afzet van 5 mln (opgevoerd van eerdere bestelling van 2.5 mln) van een buitenlandse producent is 'dus' waarschijnlijk niet van Crucell. Is m.i. waarschijnlijk van Sanofi, Novartis of GSK.
    
    Daarnaast brengt Adimmune dus zijn eigen vaccins H1N1 (flu antigen, zonder virosomen) op de markt (in ieder geval de Taiwainese) in October.
    Of Adimmune, naast het contract met Crucell voor gewone griep, ook H1N1 antigen aan Crucell gaat leveren, om in virosomen te verwerken in een speciale 'H1N1 Inflexal', is nog volledig onduidelijk. Ik zou zeggen: dat is een nieuwe overeenkomst, en zou in een PB gemeld moeten worden. Maar ja, bij Crucell weet je het nooit: soms melden ze elk mini-licentietje, en tegenwoordig LIJKEN ze heeeel weinig te melden....
    
    

15. [verwijderd] 14 juni 2009 18:37

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    kortom crucell wil mee profiteren..
    Hopelijk komt er nog een aardig persbericht uit dezer dagen om de koers verder te doen stijgen
16. [verwijderd] 14 juni 2009 19:55

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    harvester schreef:

    uit bovenste post van flosz:
    
    ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune. Financial details were not disclosed.
    

    Je punt wat betreft Japan is nu duidelijk.
    Echter, bovenstaande quote/overeenkomst geldt voor reguliere flu. Niet duidelijk is wanneer AdImmune begint (of al begonnen is) met zijn eigen reguliere flu Inflexal-achtige virosoom-product. En voordat AdImmune met Berna/Crucell het virosoom-contract aanging, produceerden ze al 'gewoon' flu antigen voor 'gewone' griepvaccins. Wellicht dat ze, naast de virosomen, deze 'gewone' vaccins ook nog gewoon aanbieden.
    
    Nu is het nieuwe gegeven dat AdImmune ook H1N1 antigen gaat maken. Het is echt nog maar de vraag of AdImmune de virosoom technologie ook maar direct inzet om van dit H1N1 antigen ook virosoom vaccins te maken. Waarschijnlijker lijkt me dat ze 'gewone' H1N1 vaccins er van maken, zonder virosoom-technologie.
    
    Net zo, is het ook maar de vraag of Crucell/Berna, naast het gecontracteerde reguliere flu antigen, H1N1 antigen van AdImmune krijgt/koopt om 'H1N1-inflexal' te maken. Vooralsnog, zonder tegenbericht ga ik uit van niet. (Als het anders zou zijn, zou het overigens een welkome meevaller zijn).
    
17. flosz 28 juni 2009 19:29

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    Taiwan lab to produce 7.5 million doses of swine flu vaccine
    Central News Agency
    Page 2
    2009-06-29 12:31 AM
    A newly built vaccine plant is set to make available 7.5 million doses of a vaccine against the influenza A(H1N1) virus, better known as swine flu, before Oct. 10 this year, the chairman of the biopharmaceutical firm Adimmune Corp. said yesterday.
    Specialists at Adimmune Corp.'s vaccine processing plant in Tanzih township, central Taiwan are currently experimenting with a virus strain that was provided by four World Health Organization (WHO)-authorized labs in Australia, Britain and the United States, Steve Chan told the CNA in an exclusive interview.
    Adimmune, the only human vaccine manufacturer in Taiwan, is scheduled to complete the experimental process and decide on a vaccine strain for mass domestic production by the end of August, said Chan. This would pave the way for animal and human trials of the A(H1N1) vaccine in September, he added.
    Chan, who served as Taiwan's health minister between 1997 and 2000, said the human clinical trials are scheduled to be completed by the end of September, giving the vaccine producer enough time to begin mass producing the A(H1N1) vaccine around Double Ten National Day on Oct. 10.
    If all goes according to plan, Taiwan will become the 12th country in the world capable of producing A(H1N1) vaccines, he said.
    Adimmune's Tanzih plant, in working toward this goal, will advance its original launch schedule by 18 months, as it had planned to begin mass production of vaccines against normal influenza in 2011 for export, he added
    tinyurl.com/mx5lw6
    
18. [verwijderd] 28 juni 2009 19:56

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    flosz schreef:

    Taiwan lab to produce 7.5 million doses of swine flu vaccine
    Central News Agency
    Page 2
    2009-06-29 12:31 AM
    A newly built vaccine plant is set to make available 7.5 million doses of a vaccine against the influenza A(H1N1) virus, better known as swine flu, before Oct. 10 this year, the chairman of the biopharmaceutical firm Adimmune Corp. said yesterday.
    Specialists at Adimmune Corp.'s vaccine processing plant in Tanzih township, central Taiwan are currently experimenting with a virus strain that was provided by four World Health Organization (WHO)-authorized labs in Australia, Britain and the United States, Steve Chan told the CNA in an exclusive interview.
    Adimmune, the only human vaccine manufacturer in Taiwan, is scheduled to complete the experimental process and decide on a vaccine strain for mass domestic production by the end of August, said Chan. This would pave the way for animal and human trials of the A(H1N1) vaccine in September, he added.
    Chan, who served as Taiwan's health minister between 1997 and 2000, said the human clinical trials are scheduled to be completed by the end of September, giving the vaccine producer enough time to begin mass producing the A(H1N1) vaccine around Double Ten National Day on Oct. 10.
    If all goes according to plan, Taiwan will become the 12th country in the world capable of producing A(H1N1) vaccines, he said.
    Adimmune's Tanzih plant, in working toward this goal, will advance its original launch schedule by 18 months, as it had planned to begin mass production of vaccines against normal influenza in 2011 for export, he added
    tinyurl.com/mx5lw6
    
    

    Will this be tradional(egg-based) vaccine? Wonder how much they are getting paid, and does Crucell get a cut.
19. flosz 28 juni 2009 20:17

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    Van Pagina 1 vd draadje:
    Taiwan`s first vaccine production plant to be operational in 2009
    
    Taipe (ANTARA News/Asia Pulse) - The ADImmune Corporation (ADI) unveiled plans Tuesday to operate Asia's first vaccine production plant in line with European standards, with an aim to provide adequate supplies of influenza vaccines and to develop new vaccines.
    
    Under the NT$2.8-billion (US$87.28 million) project, the plant is expected to be completed next year and it will have the capacity to produce more than 30 million doses of egg-based influenza vaccines per year, according to ADI's chairman and CEO Chi Steve Chan.
    
    The vaccines target markets both at home and abroad through the network of the Dutch company Crucell, Chan said, adding that his company's products will be the first from Asia to be sold on the European market.
    
    Foto:
    Workers remove trays of eggs from a rack at the AdImmune flu vaccine manufacturing facility in Taichung
    www.allvoices.com/news/3537569-swine-...
    ********************
    En post weer verdwenen van Yahoo.....gr!
    

    Bijlage:
20. [verwijderd] 28 juni 2009 21:08

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    flosz schreef:

    Van Pagina 1 vd draadje:
    Taiwan`s first vaccine production plant to be operational in 2009
    
    Taipe (ANTARA News/Asia Pulse) - The ADImmune Corporation (ADI) unveiled plans Tuesday to operate Asia's first vaccine production plant in line with European standards, with an aim to provide adequate supplies of influenza vaccines and to develop new vaccines.
    
    Under the NT$2.8-billion (US$87.28 million) project, the plant is expected to be completed next year and it will have the capacity to produce more than 30 million doses of egg-based influenza vaccines per year, according to ADI's chairman and CEO Chi Steve Chan.
    
    The vaccines target markets both at home and abroad through the network of the Dutch company Crucell, Chan said, adding that his company's products will be the first from Asia to be sold on the European market.
    
    Foto:
    Workers remove trays of eggs from a rack at the AdImmune flu vaccine manufacturing facility in Taichung
    www.allvoices.com/news/3537569-swine-...
    ********************
    En post weer verdwenen van Yahoo.....gr!
    
    

    I know that Adimmune will eventually be providing some antigen for Crucell to make Inflexal...will Adimmune ever be making "Inflexal" also, a virosome based flu shot? Also, Crucell has been doing tests to see if they can lower the dosage by injecting it intradermally(?), and therefore may be able to sell twice as many flu "shots" with the same amount of antigen. How is that coming?
21. [verwijderd] 28 juni 2009 21:54

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ron banged schreef:

    I know that Adimmune will eventually be providing some antigen for Crucell to make Inflexal...will Adimmune ever be making "Inflexal" also, a virosome based flu shot?
    

    Original PR:
    
    Crucell announces influenza alliance with ADImmune Corporation
    Published: 08:00 22.03.2007 GMT+1 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562
    Crucell announces influenza alliance with ADImmune Corporation
    Leiden, The Netherlands, March 22, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has completed an influenza alliance with Taiwanese-based ADImmune Corporation. Under the terms of the deal, ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune. Financial details were not disclosed.
    
    "With the demand for Inflexal® V presently beating current market supply, Crucell is convinced of an excellent growth potential for its influenza vaccine," said Dr. Ronald H.P. Brus, Crucell's President and Chief Executive Officer. "Inflexal® V is a distinguishable product that we intend to expand further into existing and new markets. The future additional supply of antigen from ADImmune will increase our possibilities to do this."